By Kamal Choudhury (Reuters) -Vaccine maker Novavax's shares plunged nearly 20% at market close on Thursday, after Health and ...

Shares of Novavax Inc. NVAX tumbled 19.56% to $5.43 Thursday, on what proved to be an all-around dismal trading session for ...

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Shares in US biotech Novavax fell more than 20% before the weekend, following remarks from health and human services ...

Novavax, the little-known Maryland company that received a $1.6 billion deal from the federal government for its experimental coronavirus vaccine, announced encouraging results in two preliminary ...

The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on ...

Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID ...

Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 ...

Novavax (NasdaqGS:NVAX) experienced a noteworthy 13% increase in its share price last week, coinciding with significant changes in its leadership. The retirement of James Young as Chair of the Board ...

Novavax started the week hoping the FDA would issue a full approval of its Covid vaccine. But the decision never came.

Health secretary Robert F. Kennedy Jr. has expressed another unorthodox view on vaccines, with the long-time vaccine critic declaring that vaccines for respiratory bugs that target a sole part of ...